首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1534272

全球特發性肺纖維化治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Idiopathic Pulmonary Fibrosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球特發性肺纖維化治療市場的需求預計將從2023年的45.4億美元達到2032年近138.4億美元的市場規模，2024-2032年研究期間的複合年成長率為13.18%。

特發性肺纖維化 (IPF) 是一種慢性進行性肺部疾病，其特徵是肺部疤痕組織累積（纖維化），導致呼吸障礙和氧氣吸收減少。 IPF 的確切病因尚不清楚，因此為特發性。這種情況會導致持續咳嗽、氣短和肺功能進行性下降。特發性肺纖維化治療方案旨在減緩疾病的進展、控制症狀並改善生活品質。這些可能包括針對纖維化過程的抗纖維化藥物，例如吡非尼酮和尼達尼布，以及氧氣治療和肺部復健等支持療法。治療的目標是穩定肺功能、緩解症狀並提供支持性護理以提高患者的整體健康狀況。

市場動態

由於 IPF 盛行率的不斷增加、其進行性以及相關的未滿足的醫療需求，特發性肺纖維化治療市場正在經歷成長。隨著全球人口老化和對 IPF 認知的提高，對能夠解決這種具有挑戰性的疾病的複雜性的治療方法的需求不斷成長。研究和藥物開發的進步是市場成長的重要驅動力。吡非尼酮和尼達尼布等抗纖維化療法的最新突破已證明可減緩疾病進展和改善患者預後。對新型治療藥物和聯合療法的持續研究為 IPF 管理的進一步進步提供了潛力。基於遺傳和分子譜的標靶治療和個人化醫療方法的發展也為特發性肺纖維化治療市場的擴張提供了機會。對臨床試驗和研究計劃的投資增加有助於特發性肺纖維化治療市場的成長。製藥公司、研究機構和醫療保健提供者之間的合作旨在增進對該疾病的了解並開發創新療法。此外，擴大醫療基礎設施和改善獲得專業護理的機會可以提高 IPF 療法的可用性和採用率。對以患者為中心的方法和支持性護理策略的日益關注進一步支持了市場成長。整合藥物和非藥物干預措施的患者宣傳、教育和綜合護理模式有助於改善患者的生活品質並支持整體疾病管理。然而，高昂的治療成本和有限的患者訪問可能會限制市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球特發性肺纖維化治療市場的各個細分市場進行了包容性評估。特發性肺纖維化治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

特發性肺纖維化治療市場報告的這一部分提供了有關國家和區域級別細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按藥物類別

Mapk 抑制劑 (Esbriet)
酪胺酸抑制劑（Ofev）
自分泌運動因子抑制劑 (GLPG 1690)

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲特發性肺纖維化治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。特發性肺纖維化治療市場的主要參與者包括霍夫曼·拉羅氏有限公司、勃林格殷格翰國際有限公司、Galapagos、FibroGen Inc.、Prometic Life Sciences Inc.、百時美施貴寶公司、MediciNova Inc .、默克公司。、新產品發布，以及其他進度。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 7 章：特發性肺纖維化治療公司的競爭格局

特發性肺纖維化治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 8 章：公司簡介

頂級公司市佔率分析
市場集中度
F. Hoffman La-Roche Ltd

公司概況
公司收入
產品
最新動態

Boehringer Ingelheim International GmbH

公司概況
公司收入
產品
最新動態

Galapagos

公司概況
公司收入
產品
最新動態

FibroGen Inc.

公司概況
公司收入
產品
最新動態

Prometic Life Sciences Inc.

公司概況
公司收入
產品
最新動態

Bristol-Myers Squibb Company

公司概況
公司收入
產品
最新動態

MediciNova Inc.

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

Merck & Co

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112115350

The global demand for Idiopathic Pulmonary Fibrosis Treatment Market is presumed to reach the market size of nearly USD 13.84 Billion by 2032 from USD 4.54 Billion in 2023 with a CAGR of 13.18% under the study period 2024-2032.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by accumulated scar tissue (fibrosis) in the lungs, leading to respiratory impairment and decreased oxygen absorption. The exact cause of IPF is unknown, making it idiopathic. The condition results in persistent cough, shortness of breath, and progressive lung function decline. Idiopathic pulmonary fibrosis treatment options are designed to slow the progression of the disease, manage symptoms, and enhance quality of life. These may include antifibrotic medications, such as pirfenidone and nintedanib, which target the fibrosis process, and supportive therapies like oxygen therapy and pulmonary rehabilitation. The goal of treatment is to stabilize lung function, alleviate symptoms, and provide supportive care to enhance patients' overall well-being.

MARKET DYNAMICS

The idiopathic pulmonary fibrosis treatment market is experiencing growth driven by the increasing prevalence of IPF, its progressive nature, and the associated high unmet medical need. As the global population ages & awareness of IPF rises, there is a growing need for therapies that can address the complexities of this challenging condition. Advancements in research and drug development are significant drivers of market growth. Recent breakthroughs in antifibrotic therapies, such as pirfenidone and nintedanib, have demonstrated efficacy in slowing disease progression and improving patient outcomes. Ongoing research into novel therapeutic agents and combination therapies offers potential for further advancements in IPF management. The development of targeted treatments & personalized medicine approaches based on genetic and molecular profiles also presents opportunities for idiopathic pulmonary fibrosis treatment market expansion. Increased investment in clinical trials and research initiatives contributes to the growth of the idiopathic pulmonary fibrosis treatment market. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers aim to advance understanding of the disease and develop innovative treatments. Additionally, expanding healthcare infrastructure and improved access to specialized care enhance the availability and adoption of IPF therapies. The rising focus on patient-centric approaches and supportive care strategies further supports market growth. Patient advocacy, education, and comprehensive care models integrating pharmacologic and non-pharmacologic interventions help improve patient quality of life and support overall disease management. However, high treatment costs and limited patient access may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Idiopathic Pulmonary Fibrosis Treatment. The growth and trends of Idiopathic Pulmonary Fibrosis Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Idiopathic Pulmonary Fibrosis Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Mapk Inhibitors (Esbriet)
Tyrosine Inhibitors (Ofev)
Autotaxin Inhibitors (GLPG 1690)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Idiopathic Pulmonary Fibrosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Idiopathic Pulmonary Fibrosis Treatment market include F. Hoffman La-Roche Ltd, Boehringer Ingelheim International GmbH, Galapagos, FibroGen Inc., Prometic Life Sciences Inc., Bristol-Myers Squibb Company, MediciNova Inc., Merck & Co. Inc., Novartis AG, Merck & Co. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. IDIOPATHIC PULMONARY FIBROSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data Analysis By Drug Class
5.3. Mapk Inhibitors (Esbriet) Historic and Forecast Sales By Regions
5.4. Tyrosine Inhibitors (Ofev) Historic and Forecast Sales By Regions
5.5. Autotaxin Inhibitors (GLPG 1690) Historic and Forecast Sales By Regions

6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

6.1. Regional Outlook
6.2. Introduction
6.3. North America Sales Analysis
- 6.3.1 Overview, Historic and Forecast Data Sales Analysis
- 6.3.2 North America By Segment Sales Analysis
- 6.3.3 North America By Country Sales Analysis
- 6.3.4 United States Sales Analysis
- 6.3.5 Canada Sales Analysis
- 6.3.6 Mexico Sales Analysis
6.4. Europe Sales Analysis
- 6.4.1 Overview, Historic and Forecast Data Sales Analysis
- 6.4.2 Europe By Segment Sales Analysis
- 6.4.3 Europe By Country Sales Analysis
- 6.4.4 United Kingdom Sales Analysis
- 6.4.5 France Sales Analysis
- 6.4.6 Germany Sales Analysis
- 6.4.7 Italy Sales Analysis
- 6.4.8 Russia Sales Analysis
- 6.4.9 Rest Of Europe Sales Analysis
6.5. Asia Pacific Sales Analysis
- 6.5.1 Overview, Historic and Forecast Data Sales Analysis
- 6.5.2 Asia Pacific By Segment Sales Analysis
- 6.5.3 Asia Pacific By Country Sales Analysis
- 6.5.4 China Sales Analysis
- 6.5.5 India Sales Analysis
- 6.5.6 Japan Sales Analysis
- 6.5.7 South Korea Sales Analysis
- 6.5.8 Australia Sales Analysis
- 6.5.9 South East Asia Sales Analysis
- 6.5.10 Rest Of Asia Pacific Sales Analysis
6.6. Latin America Sales Analysis
- 6.6.1 Overview, Historic and Forecast Data Sales Analysis
- 6.6.2 Latin America By Segment Sales Analysis
- 6.6.3 Latin America By Country Sales Analysis
- 6.6.4 Brazil Sales Analysis
- 6.6.5 Argentina Sales Analysis
- 6.6.6 Peru Sales Analysis
- 6.6.7 Chile Sales Analysis
- 6.6.8 Rest of Latin America Sales Analysis
6.7. Middle East & Africa Sales Analysis
- 6.7.1 Overview, Historic and Forecast Data Sales Analysis
- 6.7.2 Middle East & Africa By Segment Sales Analysis
- 6.7.3 Middle East & Africa By Country Sales Analysis
- 6.7.4 Saudi Arabia Sales Analysis
- 6.7.5 UAE Sales Analysis
- 6.7.6 Israel Sales Analysis
- 6.7.7 South Africa Sales Analysis
- 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE IDIOPATHIC PULMONARY FIBROSIS TREATMENT COMPANIES

7.1. Idiopathic Pulmonary Fibrosis Treatment Market Competition
7.2. Partnership/Collaboration/Agreement
7.3. Merger And Acquisitions
7.4. New Product Launch
7.5. Other Developments

8. COMPANY PROFILES OF IDIOPATHIC PULMONARY FIBROSIS TREATMENT INDUSTRY

8.1. Top Companies Market Share Analysis
8.2. Market Concentration Rate
8.3. F. Hoffman La-Roche Ltd
- 8.3.1 Company Overview
- 8.3.2 Company Revenue
- 8.3.3 Products
- 8.3.4 Recent Developments
8.4. Boehringer Ingelheim International GmbH
- 8.4.1 Company Overview
- 8.4.2 Company Revenue
- 8.4.3 Products
- 8.4.4 Recent Developments
8.5. Galapagos
- 8.5.1 Company Overview
- 8.5.2 Company Revenue
- 8.5.3 Products
- 8.5.4 Recent Developments
8.6. FibroGen Inc.
- 8.6.1 Company Overview
- 8.6.2 Company Revenue
- 8.6.3 Products
- 8.6.4 Recent Developments
8.7. Prometic Life Sciences Inc.
- 8.7.1 Company Overview
- 8.7.2 Company Revenue
- 8.7.3 Products
- 8.7.4 Recent Developments
8.8. Bristol-Myers Squibb Company
- 8.8.1 Company Overview
- 8.8.2 Company Revenue
- 8.8.3 Products
- 8.8.4 Recent Developments
8.9. MediciNova Inc.
- 8.9.1 Company Overview
- 8.9.2 Company Revenue
- 8.9.3 Products
- 8.9.4 Recent Developments
8.10. Merck & Co. Inc.
- 8.10.1 Company Overview
- 8.10.2 Company Revenue
- 8.10.3 Products
- 8.10.4 Recent Developments
8.11. Novartis AG
- 8.11.1 Company Overview
- 8.11.2 Company Revenue
- 8.11.3 Products
- 8.11.4 Recent Developments
8.12. Merck & Co
- 8.12.1 Company Overview
- 8.12.2 Company Revenue
- 8.12.3 Products
- 8.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Drug Class (USD MN)
Mapk Inhibitors (Esbriet) Market Sales By Geography (USD MN)
Tyrosine Inhibitors (Ofev) Market Sales By Geography (USD MN)
Autotaxin Inhibitors (GLPG 1690) Market Sales By Geography (USD MN)
Global Idiopathic Pulmonary Fibrosis Treatment Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition